Nav: Home

Researchers solve mystery of how ALL enters the central nervous system

July 18, 2018

DURHAM, N.C. - A deadly feature of acute lymphoblastic leukemia (ALL) is its invasion of the central nervous system.

ALL in the central nervous system is very difficult to treat, because most drugs are blocked from the organ system due to a "blood-brain barrier" designed to protect the brain. How cancer cells enter the central nervous system has been an unanswered question for researchers and clinicians for decades.

Now, a research team led by Duke Cancer Institute scientists has found that this blood cancer infiltrates the central nervous system not by breaching the blood-brain barrier, but by evading the barrier altogether.

Publishing in the journal Nature, the researchers describe how the cancer cells are uniquely equipped with receptors that can grasp scaffolding proteins on the outside of blood vessels like fire poles, riding them down from the bone marrow through membranes into the space filled with cerebral-spinal fluid.

"It's a very unexpected way for cells to travel into the central nervous system," said Dorothy Sipkins, M.D., Ph.D., associate professor in Duke's division of Hematologic Malignancies and Cellular Therapy. Sipkins is the senior author of the study, which is published online July 18.

"Understanding how ALL gets into the central nervous system arms us with new ways to target this pathway and hopefully shut it down," she said.

Sipkins said the finding culminates more than a decade of research in which much of that time was spent down a blind alley, looking for the key to how ALL crossed the vaunted blood-brain barrier that protects the brain from hazards in the bloodstream.

After perfecting a way to view the brains of mice in real time, she still could not see how ALL cells crossed into the central nervous system. More experiments followed, but the mystery remained unsolved, even as the assumption of a blood-brain breach continued to guide both care and research for advanced ALL.

"It was very confusing," Sipkins said. "It should be traceable, so why was it so hard to track the cells penetrating the blood-brain barrier?"

Then a key finding emerged from experiments on a drug that Sipkins's lab was testing. Mice receiving the drug were not becoming paralyzed from advanced ALL disease, which is what usually happens to the animals when cancer cells infiltrate the central nervous system. Instead, the cancer remained in the animals' bone marrow.

Upon further analysis, Sipkins found that the drug itself did not cross the blood-brain barrier, so it wasn't activating a therapeutic response in the cerebral spinal fluid. That meant that the drug was somehow preventing the cancer cells from migrating into the central nervous system.

"When we dissected the spines and the vertebrae that surround the spinal cord, we noticed this strange thing: you could see all the leukemia cells in the vertebral bone marrow and it looked like they were streaming through a channel at the bone surface straight into the spinal cord," Sipkins said.

But the cancer cells were not simply chewing through the bone. Instead, the researchers found, the ALL cells carry an abundance of receptors for a protein called laminin, which surrounds blood vessels and nerves to help facilitate cell migration. Tiny blood vessels pass directly through the vertebrae to the meninges tissue that lines the spinal cord and brain. The ALL cells were grabbing onto the laminin surrounding these blood vessels and zipping down into the meninges region where cerebral spinal fluid circulates.

"It just all made sense in what we see in patients, the anatomy, the molecular mechanisms," Sipkins said. "It was very exciting to piece together."

Sipkins said the investigational drug that sparked the finding could have therapeutic benefit, but needs further study. She said other molecules that work in a similar way to inhibit cell mobility could also have potential benefit.
-end-
In addition to Sipkins, study authors include Hisayuki Yao, Trevor T. Price, Gaia Cantelli, Brandon Ngo, Matthew J. Warner, Lindsey Olivere, Sarah M. Ridge, Elizabeth M. Jablonski, Joe Therrien, Stacey Tannheimer, Chad M. McCall and Anjen Chenn.

The study received support from the Duke Cancer Institute and Gilead Sciences, Inc., which provided the drug Sipkins studied that led to the finding.

Duke University Medical Center

Related Cancer Cells Articles:

Cancer cells send signals boosting survival and drug resistance in other cancer cells
Researchers at University of California San Diego School of Medicine report that cancer cells appear to communicate to other cancer cells, activating an internal mechanism that boosts resistance to common chemotherapies and promotes tumor survival.
A protein that stem cells require could be a target in killing breast cancer cells
Researchers have identified a protein that must be present in order for mammary stem cells to perform their normal functions.
Single gene encourages growth of intestinal stem cells, supporting 'niche' cells -- and cancer
A gene previously identified as critical for tumor growth in many human cancers also maintains intestinal stem cells and encourages the growth of cells that support them, according to results of a study led by Johns Hopkins researchers.
Prostate cancer cells grow with malfunction of cholesterol control in cells
Advanced prostate cancer and high blood cholesterol have long been known to be connected, but it has been a chicken-or-egg problem.
Immune therapy scientists discover distinct cells that block cancer-fighting immune cells
Princess Margaret Cancer Centre scientists have discovered a distinct cell population in tumours that inhibits the body's immune response to fight cancer.
New system developed that can switch on immune cells to attack cancer cells
Researchers have developed an artificial structure that mimics the cell membrane, which can switch on immune cells to attack and destroy a designated target.
Hybrid immune cells in early-stage lung cancer spur anti-tumor T cells to action
Researchers have identified a unique subset of these cells that exhibit hybrid characteristics of two immune cell types -- neutrophils and antigen-presenting cells -- in samples from early-stage human lung cancers.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Sleep hormone helps breast cancer drug kill more cancer cells
Tiny bubbles filled with the sleep hormone melatonin can make breast cancer treatment more effective, which means people need a lower dose, giving them less severe side effects.
Breast cancer tumor-initiating cells use mTOR signaling to recruit suppressor cells to promote tumor
Baylor College of Medicine researchers report a new mechanism that helps cancer cells engage myeloid-derived suppressor cells.

Related Cancer Cells Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Moving Forward
When the life you've built slips out of your grasp, you're often told it's best to move on. But is that true? Instead of forgetting the past, TED speakers describe how we can move forward with it. Guests include writers Nora McInerny and Suleika Jaouad, and human rights advocate Lindy Lou Isonhood.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...